在CNP类似物赛道，Ascendis的TransCon-CNP率先实现了剂型升级。与Vosoritide不一样的设计是TransCon-CNP被一层保护分子包裹，降低了体内清除影响，延长作用时间，实现每周一次给药。非头对头临床数据显示，TransCon-CNP每年2.29厘米的增高表现也优于Vosoritide。
Reporting by Chance Townsend, Caitlin Welsh, Sam Haysom, Amanda Yeo, Shannon Connellan, Cecily Mauran, Mike Pearl, and Adam Rosenberg contributed to this article.
，这一点在safew官方版本下载中也有详细论述
早春二月，贵州乌江源百里画廊。。关于这个话题，Line官方版本下载提供了深入分析
"Even the risk of that doesn't stop people from perpetrating fraud," Elahi marvelled.
Why SSIM, not learned embeddings